A vaccine development platform
At Hafion, we are combining two innovative technologies to create a single vaccine that broadly protects against a range of bacterial strains. Live-attenuated vaccines generally protect against only one or two strains of bacteria. By targeting the shared common characteristics between all serotypes, we can encourage the body to produce antibodies that defend against many more.
It sounds simple but it’s actually a complex platform involving a protein fragment antigen complex and a nanoparticle delivery system. To make it happen, our researchers are applying their specialized experience in vaccines and microbiology.
The Pseudomonas aeruginosa vaccine.
We are starting with a single vaccine that protects against all Pseudomonas aeruginosa (Pa) strains affecting humans. Pa causes serious infections in humans, particularly in the critically ill, the immunocompromised, those with burn wounds or combat-related wound infections, and those with cystic fibrosis. Yet, no approved vaccine exists.
Serious infections from Pa generally occur only in healthcare (nosocomial) settings, but people can also develop mild infections in other environments. Pa infection becomes more common with increasing duration of intubation or hospitalization.
Most Pa strains are resistant to many antibiotics limiting the treatment options. Our vaccine to prevent Pa, regardless of initial injury, will positively impact all of us because as we age, we all have a greater risk of a potential Pa infection. Our vaccine is aimed at preventing these difficult to treat infections.
We use our unique combination of scientific expertise, strategic partnerships, and strong collaborative team to develop a Pa vaccine to prevent illness and save lives. For us, this is just the beginning. We have big plans for future vaccines to save even more lives.